Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin

Imran Nizamuddin, Carlos Galvez, Barbara Pro*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Peripheral T-cell lymphomas (PTCL) are rare lymphoproliferative disorders with poor outcomes and high rates of relapse. Incidence varies although the most common subtypes include PTCL-not-otherwise specified, anaplastic large cell lymphoma, and angioimmunoblastic T-cell lymphoma. Anaplastic large cell lymphoma is characterized by near-universal CD30 expression and serves as a prototypic model for other CD30-expressing lymphomas. Historically, these neoplasms have been treated with regimens used in the treatment of aggressive B-cell lymphomas. Over the last decade, brentuximab vedotin, an antibody-drug conjugate, has been investigated to treat peripheral T-cell lymphomas expressing CD30. While first studied in the relapsed and refractory setting, it was later studied in the frontline setting in the ECHELON-2 trial with positive results and is now an approved treatment for CD30-expressing peripheral T-cell lymphomas. Other treatment options in the relapsed and refractory setting include histone deacetylase inhibitors, pralatrexate, and salvage multiagent chemotherapy regimens. Current research is underway regarding combination therapies and the use of other novel agents.

Original languageEnglish (US)
Pages (from-to)85-94
Number of pages10
JournalSeminars in Hematology
Volume58
Issue number2
DOIs
StatePublished - Apr 2021

Keywords

  • Anaplastic large cell lymphoma
  • Brentuximab vedotin
  • CD30
  • ECHELON-2
  • T-cell lymphoma

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin'. Together they form a unique fingerprint.

Cite this